- Report
- September 2025
- 250 Pages
Global
From €3932EUR$4,490USD£3,413GBP
- Report
- March 2023
- 147 Pages
Global
From €4334EUR$4,949USD£3,762GBP
- Report
- January 2024
- 156 Pages
United States
€3328EUR$3,800USD£2,889GBP
- Report
- January 2024
- 114 Pages
United States
€3065EUR$3,500USD£2,661GBP
Serevent is a brand of salmeterol, a long-acting beta-agonist (LABA) used to treat asthma and chronic obstructive pulmonary disease (COPD). It is used as a maintenance treatment to prevent and reduce the frequency of asthma attacks, and to reduce the severity of COPD symptoms. It is usually taken twice daily, either as an inhaler or a dry powder inhaler. Serevent is part of a class of drugs known as bronchodilators, which work by relaxing the muscles in the airways, allowing air to flow more freely.
The Serevent market is a subset of the larger respiratory drugs market, which includes a variety of treatments for asthma, COPD, and other respiratory conditions. These treatments include inhaled corticosteroids, long-acting muscarinic antagonists, and short-acting beta-agonists, as well as other medications.
Some companies in the Serevent market include GlaxoSmithKline, Merck, and Novartis. Show Less Read more